Treating in Medical Technology

New AHRQ Study Finds Mixed Evidence on Use of Radiofrequency Catheter Ablation for Treating Atrial Fibrillation

ROCKVILLE, Md., July 6 /PRNewswire-USNewswire/ -- A procedure that sends targeted energy into the heart through a catheter can be used to treat a common type of irregular heartbeat, but little is known about the treatment's long-term benefits and the best methods and circumstances for applying it,...

AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain

Study in major abdominal surgery patients achieved primary and secondary endpoints REDWOOD CITY, Calif., June 29 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. today announced positive results from the second Phase 2 clinical study evaluating the safety and efficacy of its ARX-01 Sufentanil Nan...

Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms

LINTHICUM, Md., April 27 /PRNewswire-USNewswire/ -- Men taking generic drugs may be more likely to have less effective results and more adverse events than if they were using branded medications, according to new data from researchers in New York. Researchers presented a study at the 104th Annual ...

New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers

SYDNEY, April 20 /PRNewswire/ -- Australian medical research company Immune System Therapeutics Ltd (IST) has launched a clinical trial to test its breakthrough treatment for terminal blood cancers. IST has genetically engineered an antibody drug that binds specifically to a target protein fo...

NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection

EMERYVILLE, Calif., March 7 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Alternext: NBY), a mid-stage biopharmaceutical company developing first-in-class, novel, synthetic anti-infective products for the treatment and prevention of a wide range of bacterial, fungal, and viral infe...

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer

OSLO, Norway, January 14 /PRNewswire-FirstCall/ -- - Results Highlight the Potential of Alpharadin to Treat Bone Metastases in Major Cancer Indications Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that with the results of the BC1-04 study reported today i...

AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety

Results Show Successful Clinical Validation of Pharmacodynamic Effect REDWOOD CITY, Calif., Jan. 12 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions with an initial emphasis on pain...

Alexza's AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial

MOUNTAIN VIEW, Calif., Dec. 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced positive results from its second Phase 3 clinical trial of AZ-004 (Staccato(R) loxapine). This Phase 3 clinical trial was conducted in patients with bipolar disorder experiencing...

First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting

CHESHIRE, Conn., Dec. 7 /PRNewswire-FirstCall/-- Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), was associated with an improvement in hematologic parameters in a l...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

Company reaffirms its innovation leadership and long-term commitment to hepatitis research KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today provided a clinical update on boceprevir, its lead investigational oral hepatitis C protease inhi...

Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids

- Results demonstrate clinically significant reduction in allergic asthma attacks and further define Xolair safety profile in children age six through 11 - this includes 11-year-old children, up to their 12th birthday - Xolair is the only approved therapy to block IgE, which is associated wi...

NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy

Data presented at annual ICAAC/IDSA meeting in Washington, D.C. WASHINGTON, Oct. 27 /PRNewswire/ -- A novel topical therapy for nail fungus, NB-002, has demonstrated a new topical approach to healing nail fungus by penetrating skin pores and diffusing through the skin that surrounds the en...

Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections

Iclaprim also achieved high eradication rates for the most common pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) REINACH, Switzerland, Oct. 26 /PRNewswire-FirstCall/ -- Arpida (SWX: ARPN) today presented the combined results from two pivotal Phase III clinical tri...

Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure

Company Targeting to Complete Enrollment of 150 patients by March 2009 SUNRISE, Fla., Sept. 30 /PRNewswire-FirstCall/ -- Bioheart, Inc., (Nasdaq: BHRT ), today announced that 35 of the leading U.S. Heart Failure Centers have engaged in Bioheart's Phase II/III MARVEL(1) Trial of myogenic cel...

Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients

BOSTON, Sept. 24 /PRNewswire-FirstCall/ -- Cancer treatment specialists reported yesterday how new technologies are enabling them to provide faster, more accurate cancer treatments than was possible with earlier generations of radiotherapy technology. In presentations given at an "Emerging Tec...

Alexza's AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients

Conference Call Scheduled for Today - Tuesday, September 2, 2008 at 5:00 p.m. Eastern Time MOUNTAIN VIEW, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced positive results from its first Phase 3 clinical trial of ...

NJ-Based Surgeon Helps Pioneer Dramatic Advance in Treating Damaged Discs

Total Disc Replacement implant represents newest alternative surgical treatment Dr. Carl Giordano - based in Morristown - among first surgeons selected to provide operation Dramatic reduction in post-surgery pain and stiffness; quicker ...

TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate

TorreyPines Therapeutics' CEO Neil Kurtz, M.D., to Moderate Discussion Following Presentations by Tony Yaksh, Ph.D.; Jerome Goldstein, M.D.; and Alan J. Tuchman, M.D. LA JOLLA, Calif., June 25 /PRNewswire/ -- A Webinar hosted by TorreyPines Therapeutics, Inc. (Nasdaq:...

New Meta-Analysis Confirms Safety Profile for NeoRecormon in Treating Anaemia in Cancer Patients

BASEL, Switzerland, June 11 /PRNewswire-FirstCall/ -- - Data Published in the British Journal of Cancer Reports That NeoRecormon use has no Negative Impact on Overall Survival or Tumour Progression A new meta-analysis of all 12 prospective, randomised, controlled studies in 2,301 cancer pa...

New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma

Gene Expression Profiling of Tumor is Correlated With Clinical Response CHICAGO, May 30 /PRNewswire-FirstCall/ -- New data presented by GlaxoSmithKline (GSK) today highlighted the potential of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) through results of three...

Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas

TAMPA, Fla., April 29 /PRNewswire/ -- Quantum Immunologics, Inc. ("QI") announces the commencement of a Phase I/II clinical trial to assess the safety and efficacy of a novel anti-cancer vaccine/immunotherapy that will be used on patients with Stage IV advanced breast cancer. Patients accepted...

Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing

- Second research program centered on potential target in inflammatory indications such as rheumatoid arthritis - NUTLEY, N.J., April 15 /PRNewswire/ -- Roche announced today that it will acquire Piramed Limited, a privately-owned UK company focusing on therapeutics targeting PI...

Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure

Leading Expert Discusses Study During Late-Breaking Presentations at ACC CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT ) announced today that final six-month, follow-up patient data was presented today during the late-breaking clinical trial sessions at the Ame...

Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure

Leading Expert Discusses Study During Late-Breaking Presentations at ACC CHICAGO, April 1, 2008 /PRNewswire/ -- Final six-month, follow-up patient data presented today during the late-breaking clinical trial sessions at the American College of Cardiology, suggest MyoCell(R) myoblast clinical c...

Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients

- ACCOMPLISH first study to compare two single-pill combinations of commonly used high blood pressure medicines in reduction of cardiovascular events - RAS inhibition with an ACEI was the foundation of the combination therapies in this study and exceptional b...

New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies

- Human Genome Sciences' ABthrax(TM) shows lifesaving potential - - HGS on track to deliver 20,000 doses to Strategic National Stockpile beginning in 2008 - ROCKVILLE, Md., Dec. 18 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today annou...

Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics' Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache

- Company Plans to Initiate Phase IIa Study of NGX426 in Acute Migraine in First Half of 2008 - LA JOLLA, Calif., Dec. 10 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) today reported pharmacokinetic data obtained in a Phase I maximum tolerated dose cli...

Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis

Findings reinforce the benefits of Asacol for ulcerative colitis patients AVENTURA, Fla., Dec. 5 /PRNewswire/ -- Data from two Phase III clinical trials support that Asacol, an oral, non-steroidal medication that belongs to the class of agents known as 5-aminosalicylic acids (5-ASAs), is an eff...

Penn Research Shows Transcranial Magnetic Stimulation Effective in Treating Major Depression

Non-drug, non-invasive treatment helps patients who have tried other options without success PHILADELPHIA, Nov. 26 /PRNewswire-USNewswire/ -- Researchers at the University of Pennsylvania School of Medicine and other study sites have found that transcranial magnetic stimulation (TMS) --...

Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease

NEW ORLEANS, Nov. 12 /PRNewswire/ -- Two studies being presented at the American Academy of Ophthalmology's 2007 Annual Meeting suggest that telemedicine may have a significant role to play in the diagnosis of eye diseases, increased patient compliance and patient access to quality care. In t...

Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications

-Study Published in Neurogastroenterology and Motility- MONTVALE, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (AMEX: SYI ) announced today the publication of preclinical data demonstrating the ability of its compound, alagebrium, to reduce serum levels of advanced gly...

Edwards' Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg

- Arterial Blockages in the Leg are Estimated to Affect 8 Million Americans - WASHINGTON, Oct. 23 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW ), a world leader in products and technologies to treat advanced cardiovascular disease, today...

New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections

RARITAN, N.J., Oct. 8 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. today announced results from a Phase III trial that showed that investigational antibiotic ceftobiprole was found to clinically cure 86% of patients with diabetic foot infections -- including ...

Evidence of Benefit Lacking for Many Common Ways of Treating Osteoarthritis of the Knee

ROCKVILLE, Md., Oct. 4 /PRNewswire-USNewswire/ -- A new scientific review released today by HHS' Agency for Healthcare Research and Quality concludes that evidence of benefit is lacking for many common ways of treating osteoarthritis of the knee, including popular dietary supplement ingredient...

Promising Results in Treating Facial Bruising From Injectables

Top physician leading clinical trials FREEPORT, N.Y., Sept. 26 /PRNewswire/ -- Physicians nationwide report promising results in treating facial bruising from injectable cosmetic treatments by using Pinoxide(TM), an active ingredient best known for treating under-eye circles. ...

New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients With Complicated Skin Infections, Including MRSA

CHICAGO, Sept. 18 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced that the investigational antibiotic ceftobiprole was as effective as commonly used combination therapy in treating patients with complicated skin infections caused by a broad spec...

New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias

CHICAGO, Sept. 18 /PRNewswire/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C., today announced that the investigational antibiotic doripenem was found to clinically cure 81% of patients with nosocomial pneumonia (NP), and 68% of patients with ventilator-associated pneumonia...

Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery

OAK BROOK, Ill., Aug. 16 /PRNewswire-USNewswire/ -- New research from the Washington University School of Medicine in St. Louis, Mo. indicates that endoscopic balloon dilation is a safe and effective method in treating gastrojejunal anastomotic strictures (a narrowing of the opening made betwe...

RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer

IRVING, Texas--(BUSINESS WIRE)--May 15, 2007 - Reata Pharmaceuticals, Inc. today announced the publication of an article in the May 2007 issue of the journal Cancer Research showing that RTA 402, the company's Phase 2 development candidate for cancer, was highly effective in a rigorous animal model...

Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases

Celgene to Advance Clinical and Regulatory Development of Oral Anti-Inflammatory Franchise SUMMIT, N.J., May 22, 2007 /PRNewswire-FirstCall/ -- Celgene Corporation announced its plans to advance the development of leading oral anti-inflammatory candidates across a broad range of inflammatory disea...